Showing 3411-3420 of 5069 results for "".
- GBI Research: Global Dermatology Pipeline Will See Shift Toward Increased Use of Biologicshttps://practicaldermatology.com/news/gbi-research-global-dermatology-pipeline-to-see-shift-toward-increased-use-of-biologics/2458071/The global dermatology pipeline, which currently comprises 850 products with a disclosed stage of development, is primarily made up of drugs at an early stage of development, with the late stages of the pipeline dominated by generics and biosimilars, according to GBI Research. The company
- Record Growth Noted for PCA SKINhttps://practicaldermatology.com/news/record-growth-noted-for-pca-skin/2458076/PCA SKIN® ranked as the #2 fastest growing professional skincare brand in 2017, according to the global market research and management consulting firm, Kline. Kline Company lists PCA SKIN as hav
- Bioré Skincare Partners with Girl Uphttps://practicaldermatology.com/news/bior-skincare-partners-with-girl-up/2458081/To celebrate the launch of their new Limited Edition Deep Cleansing Pore Strips, Bioré® Skincare is partnering with Girl Up™, a United Nations Foundation campaign. Girl Up mobilizes girls and women across the globe to raise awareness and funds for United Nations prog
- Survey Highlights Risks of Pubic Hair Groominghttps://practicaldermatology.com/news/survey-highlights-risks-of-pubic-hair-grooming/2458086/More than one-quarter of people who groom their pubic hair sustain grooming-related injuries, according to a new article published by JAMA Dermatology. Of the 7,570 men and women who completed
- Bonti's Novel Gateway Neuromodulator Performs Well in Phase 2A Studyhttps://practicaldermatology.com/news/bontis-novel-serotype-e-botulinum-toxin-performs-well-in-phase-2a-study/2458094/Bonti’s lead product candidate, EB- 001, passed muster in a Phase 2A study for the treatment of glabellar lines. EB-001 is a novel serotype E botulinum neurotoxin with a unique efficacy profile, characterized by fast onset of action (about 24 hours
- Environmental Groups Sue FDA to Take Formaldehyde Out of Salonshttps://practicaldermatology.com/news/environmental-groups-sue-fda-to-take-formaldehyde-out-of-salons/2458096/The Environmental Working Group (EWG) and Women’s Voices for the Earth (WVE) are suing the Food and Drug Administration (FDA) because of the group’s failure to act on dangerous hair straighteners that contain unsafe levels of formaldehyde and pose a significant health hazard to consum
- Dr. Larry Brilliant to Give Keynote at ASDS 2017 Meetinghttps://practicaldermatology.com/news/dr-larry-briiliant-to-give-keynote-at-asds-2017-meeting/2458097/Larry Brilliant, MD, MPH, Chair of the Skoll Global Threats Fund in San Francisco and former Vice President and Executive Director of Google, is slated to give the opening keynote address at The
- Glenmark Pharmaceuticals Reports Positive Phase 2a Data for GBR 830 for Atopic Dermatitishttps://practicaldermatology.com/news/glenmark-pharmaceuticals-reports-positive-phase-2a-data-for-gbr-830-for-atopic-dermatitis/2458102/Glenmark Pharmaceuticals shared positive data from a Phase 2a study of GBR 830, an investigational, anti-OX40 monoclonal antibody, for the treatment of atopic dermatitis (AD). The study evaluated the safety, biological and clinical activity, and pharmacokinetics of GBR 830, relative to placebo, i
- Innovation in Action: Meet the DNA Sunscreen that Gets Better the Longer You Wear Ithttps://practicaldermatology.com/news/innovation-in-action-meet-a-dna-sunscreen-that-gets-better-the-longer-you-wear-it/2458109/Researchers at Binghamton University, State University of New York have developed a coating made out of DNA that gets better at protecting skin from Ultraviolet light the more you expose it to the sun, and it also keeps your skin hydrated. “Ultraviolet (UV) light can actually damage
- Histogen's Growth Factor Technology Now Part of Allergan's Skin Care Linehttps://practicaldermatology.com/news/histogens-growth-factor-technology-now-part-of-allergan-skin-care-line/2458111/Histogen’s growth factor technology will be marketed as part of Allergan's skin care line within its recently acquired Regenica® Advanced Rejuvenation System. The Regenica line is based on multipotent CCM Complex (Cell Conditioned Media) which comprises active growth factors